Chimeric antigen receptor (CAR) T cell therapy is a form of T cell engineering where T cells are obtained from a patient and engineered in a laboratory to better kill the patient's cancer cells. Specifically, CAR T cells are modified to express a receptor on their surface that recognizes the specific antigen present on the patient's cancer cells.
-
The study of a single cell, the fundamental unit of our complex bodies, has become an important field in cellular biology, and researchers are using single-cell analysis to shed new light on...
In the last 5 years, the US Food and Drug Administration has approved 4 anti-CD19 chimeric antigen receptor T cell (CART19) products for relapsed/refractory B cell lymphomas and leukemia. Ho...
Webinars will be available for unlimited on-demand viewing after live event. Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the AS...
Flow cytometry plays a crucial role in the rapidly growing field of cell therapy, this method is used to identify different types of cells throughout the manufacturing process, from initial...
The expansion and persistence of CAR T cells within patients is the key to a successful treatment. Therefore, monitoring of CD19 CAR T cells following infusion is of utmost interest. The CAR...
Do you want to bring your CAR NK cell and Treg cell research into clinical applications? Watch this webinar and explore Miltenyi Biotec’s solutions to advance CAR NK cell and Treg-base...
Watch this webinar and explore Miltenyi Biotec’s solutions to advance CAR T-cell therapies – from basic research to process development and clinical manufacturing. Discover the p...
JUL 26, 2023 | 3:10 PM
C.E. CREDITS
Cell-based immunotherapy has become the new-generation cancer medicine, and “off-the-shelf” cell products that can be manufactured at large scale and distributed readily to treat...
JUL 26, 2023 | 11:20 AM
C.E. CREDITS
Chimeric antigen receptor (CAR)-reprogrammed immune cells offer exciting therapeutic potential for addressing oncology, autoimmune diseases, transplant medicine, and infections. However, cur...
Achieving consistent AAV quantification with the QuantStudio Absolute Q AutoRun dPCR Suite Accurate quantification of AAV vectors is crucial for quality control and timely decision-making du...
The therapeutic use of chimeric antigen receptor T cells has achieved significant success in the treatment of B cells malignancies. Despite promising results in mouse tumor models, a similar...
Date: March 30, 2023 Time: 5:00pm (PST), 8:00pm (EST) March 31, 2023 9:00am (JST) Chimeric antigen receptor T cell (CAR-T) therapy is still challenging in targeting solid malignancies. The q...
Date: February 15, 2023 Time: 7:00am (PST), 10:00pm (EST), 4:00pm (CET) While not all microscopy samples can fluoresce, all can scatter light, and this scattered light can be imaged. This ha...
Date: November 16, 2022 Time: 9:00am (PST), 12:00pm (EST), 6:00pm (CET) Cell therapy offers a new treatment option for a wide variety of diseases. Most cell therapies involve injecting a spe...
Date: November 09, 2022 Time: 8:00am (PST), 11:00am (EST), 5:00pm (CET) The field of cell and gene therapy is rapidly growing. In particular, the use of lentiviruses in CAR-T applications is...
Date: November 08, 2022 Time: 11:00am (PST), 2:00pm (EST), 8:00pm (CET) Developing safe and effective CAR T cell therapies is a challenging task. That’s why thinking translational earl...
Date: November 08, 2022 Time: 8:00am (PST), 11:00am (EST), 5:00pm (CEST) While flow cytometry shines by its flexibility, it requires a high level of expertise in antibody panel development,...
The CRISPR revolution has begun and shows no signs of slowing down. CRISPR-Cas nuclease-based genome editing strategies hold great promise for the treatment of genetic disorders. However, a...
COVID-19 remains a global health emergency with limited treatment options, lagging vaccine rates, and inadequate healthcare resources in the face of an ongoing calamity. The disease is chara...